Amarin to Launch Vascepa Alone with $100M Debt Financing
Amarin Corp. plc CEO Joe Zakrzewski insisted that it would be "a mistake" to assume the company's decision to launch Vascepa on its own through the use of a $100 million debt instrument meant that it had abandoned its search for a partner for the fish oil-based product it is developing for the cardiovascular disease market.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST